AVITA Medical’s RECELL GO Shows Early Success in U.K. Burn Care
Event summary
- AVITA Medical presented first U.K. clinical data on RECELL GO at the 2026 British Burn Association Annual Meeting.
- 17 burn and reconstructive surgery patients treated successfully with RECELL GO at Stoke Mandeville Hospital.
- RECELL GO demonstrated workflow benefits, including reduced procedural variability and improved operating room efficiency.
- RECELL GO is CE-marked in Europe and the U.K., and recently received regulatory authorization in Australia and New Zealand.
The big picture
AVITA Medical’s RECELL GO represents a significant advancement in autologous cell harvesting technology, offering standardized preparation and improved workflow efficiency. The successful U.K. case series underscores the potential for broader adoption in burn care, aligning with the industry’s shift toward automated, point-of-care solutions. The company’s strategic focus on regulatory approvals and clinical validation positions it to capture a larger share of the global acute wound care market.
What we're watching
- Global Expansion
- The pace at which RECELL GO gains regulatory approvals and clinical adoption in international markets.
- Workflow Efficiency
- Whether the standardized preparation and automation of RECELL GO can significantly reduce operating room variability and improve outcomes.
- Market Penetration
- How AVITA Medical leverages early success in the U.K. to expand its presence in Europe and other international markets.